Popular Articles

CeNeRx BioPharma Obtains Rights To Novel Drug Candidate For Prevention And Treatment Of Neurodegeneration Disorders
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), announced that it has obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year.
drugs without prescription
Bovie Medical Corporation Announces 510K Submission To The FDA For Its BOSS Soft Tissue Coagulation Device
Bovie Medical Corporation (the "Company") (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for Bovie"s BOSS for surgical applications where soft tissue bipolar coagulation is desired. The BOSS is the latest generation device based on Bovie"s saline enhanced sintered steel technology.
News of the day
Ilaris® Recommended For European Approval As New Biologic Drug To Treat A Rare But Serious Group Of Auto-inflammatory Diseases
The biotechnology medicine Ilaris® (canakinumab) has passed another major milestone with a recommendation for approval in the European Union to treat patients with a life-long and potentially fatal auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS). When approved, Ilaris will be the only treatment in the EU indicated for CAPS patients aged four years and older[1].
Oncology

Shedding Light On Esophageal Disease

Canadian Light (CLS) staff scientist Luca Quaroni and Dr. Alan Casson, Head of the Department of Surgery at the University of Saskatchewan (U of S) used the synchrotron"s infrared microscope to identify tissue afflicted with a condition known as Barrett"s Esophagus from chemical fingerprints associated with the disease, which can lead to esophageal cancer. The finding is published in the June, 2009 issue of the Royal Society of Chemistry journal, The Analyst. "The advantage to using microscopes with synchrotron light is that it allows us to identify chemical biomarkers inside specific cells," says Dr. Quaroni, who conducted the synchrotron analysis. "Often the differences between healthy and malignant tissue can be quite small, but the differences seen here were quite striking. This is a good proof of concept for developing a traceable technique that matches what can be seen at the macroscopic scale using microscopic samples." The team analyzed preserved samples of healthy and diseased tissue that Dr. Casson had collected during esophageal biopsies. Using a technique known as Fourier Transform Infrared Microscopy, Quaroni and Casson identified specific chemicals - known as biomarkers - within the individual cells that make up the tissue. It was found that increased concentrations of particular biomarkers such as glycoproteins were associated with the Barrett"s tissue. Barrett"s Esophagus (BE) occurs when the cells that normally line the esophagus - the tube that connects our throat to our stomach - are replaced by cells that resemble those that line the intestine. While BE only affects approximately one percent of Americans, the number of people diagnosed with the condition is on the rise, with the increasing incidence of chronic heartburn (gastro-esophageal reflux disease or GERD) considered a risk factor for developing BE. The disease in turn can lead to an aggressive form of cancer known as esophageal adenocarcinoma. Currently, diagnosing BE depends on the skill and experience of individual pathologists examining biopsy samples from patients, often relying on subjective criteria. Identifying biomarkers that can be associated with a particular condition provides an additional tool for diagnosis. Matthew Dalzell Canadian Light , Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):